May. 4 at 8:39 PM
Atossa Genetics shares rose Monday, though the move appears unrelated to the company itself and may reflect confusion with Vanda Pharmaceuticals.
Vanda announced the U.S. commercial launch of NEREUS⢠(tradipitant), the first new prescription treatment for motion sickness in over 40 years. The drug is now available nationwide and through a direct-to-consumer platform.
Motion sickness affects an estimated 65â78 million Americans. NEREUS⢠is an oral NK-1 receptor antagonist that works by blocking the brainâs vomiting center.
The drug is priced at
$85 per dose via the companyâs portal with a valid prescription, compared to a standard list price of
$255.
The FDA approved NEREUS⢠on December 30, 2025, based on two Phase 3 trials that showed it significantly reduced vomiting versus placebo in real-world sea conditions.
Atossaâs stock movement is likely driven by ticker confusion rather than company-specific news.
$ATOS $VNDA